Biogen Idec

Biogen Idec acquires Stromedix for $75 million

Wednesday, February 15, 2012 03:01 PM

Biogen Idec has acquired Stromedix, a privately held biotechnology company focused on therapies for fibrosis and organ failure, for $75 million cash.

More... »

FDA approves label change for Tysabri

Tuesday, January 24, 2012 10:48 AM

The FDA has approved a product label change for Biogen Idec/Elan’s Tysabri that will help enable individual benefit-risk assessment for patients with multiple sclerosis (MS).

More... »

Biogen Idec announces 2012 goals

Wednesday, January 11, 2012 11:15 AM

Growing its leadership position in multiple sclerosis (MS), advancing its late-state pipeline, leveraging R&D capabilities to grow its early-stage pipeline and preparing for potential launches of new high-impact therapies are among Biogen Idec’s recently announced 2012 strategic priorities.

More... »

Biogen Idec and Isis Pharmaceuticals target spinal muscular atrophy

Friday, January 6, 2012 09:58 AM

Biogen Idec and Isis Pharmaceuticals have entered into an exclusive, global option and partnership agreement under which they will jointly develop and commercialize ISIS-SMNRx, an antisense investigational drug that treats spinal muscular atrophy (SMA) by compensating for the underlying genetic defect that causes the disease.

More... »

Biogen Idec, UCB partner in ALS research

Monday, December 19, 2011 02:39 PM

The ALS Therapy Development Institute (ALS TDI) has formed a research agreement with Biogen Idec and UCB to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's or Motor Neuron Disease. Financial terms of the agreement were not disclosed.

More... »

Samsung, Biogen establish $300m partnership in biosimilar development

Tuesday, December 6, 2011 02:25 PM

Samsung and Biogen Idec have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing in protein engineering and biologics manufacturing.

More... »

Report: Boston, N.J., Bay area lead nation’s top 16 life sciences clusters, all are growing

Monday, December 5, 2011 09:18 AM

Move over Boston, New Jersey and the San Francisco Bay area. Los Angeles and the Washington, D.C., region are quickly gathering steam as established life sciences hubs. And Minneapolis, Chicago, Denver, Houston, Florida, Atlanta and Indianapolis are among the emerging hubs not far behind. 

More... »

Cubist Pharmaceuticals names senior VP

Tuesday, October 18, 2011 10:06 AM

Cubist Pharmaceuticals has named Jennifer Jackson, Ph.D., senior vice president of regulatory affairs. Jackson will oversee all facets of Cubist’s regulatory affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities. Jackson will report to Steve Gilman, Ph.D., Cubist’s executive vice president of research and development and chief scientific officer.

More... »

Report: U.S. medical innovation at risk without funding

Thursday, October 6, 2011 12:03 PM

U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investment away from the United States towards Europe and Asia, according to a report by the National Venture Capital Association'sMedIC Coalition.

More... »

Biogen Idec names VP, global commercial operations

Thursday, September 29, 2011 10:58 AM

Biogen Idec has named Tony Kingsley executive vice president, global commercial operations, effective November 7th. Kingsley will oversee development and execution of Biogen Idec’s global commercial business strategies, reporting directly to chief executive officer George A. Scangos, Ph.D. Dr. Francesco Granata, who has headed global commercial operations since early 2010, is leaving to pursue other opportunities but will remain at the company through the end of February.

More... »